MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 892 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cobimetinib (R-enantiomer)
CAS:Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.Fórmula:C21H21F3IN3O2Pureza:98%Cor e Forma:SolidPeso molecular:531.318JNK3 inhibitor-8
JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.Fórmula:C32H30FN7O3Cor e Forma:SolidPeso molecular:579.62NUCC-0200808
NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.Cor e Forma:Odour SolidKRAS inhibitor-38
CAS:KRAS Inhibitor-38 (Example 18) is a potent inhibitor capable of effectively suppressing the activity of KRAS G12C, KRAS G12D, and KRAS G12V in vivo.Fórmula:C53H68ClF2N9O8SCor e Forma:SolidPeso molecular:1064.68HSND80
HSND80 (Compound 1) is an orally active MNK/p70S6K inhibitor, exhibiting a Kd value of 44 nM for MNK1 and 4 nM for MNK2. The residence time of HSND80 on MNK1 and MNK2 is 45 minutes and 58 minutes, respectively. HSND80 effectively inhibits non-small cell lung cancer (NSCLC) both in vitro and in vivo, and suppresses the growth of triple-negative breast cancer (TNBC) cells in vitro.Cor e Forma:Odour SolidSIAIS562055
SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.Fórmula:C49H62F3N7O5SCor e Forma:SolidPeso molecular:918.12FAM49B (190-198) mouse
CAS:FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.Fórmula:C49H71N9O14SCor e Forma:SolidPeso molecular:1042.2DS03090629
DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.Fórmula:C25H26ClN5O2Cor e Forma:SolidPeso molecular:463.96KG5
CAS:<p>KG5 inhibits PDGFRβ, B-Raf, FLT3, KIT, c-Raf; has anticancer and antiangiogenic effects; Kd: 520 nM (PDGFRβ), 300 nM (PDGFRα).</p>Fórmula:C20H16F3N7OSPureza:98.32%Cor e Forma:SolidPeso molecular:459.45PROTAC MEK1 Degrader-1
CAS:PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Fórmula:C53H66FIN8O11S2Pureza:98%Cor e Forma:SolidPeso molecular:1201.17BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Fórmula:C47H62N8O4SCor e Forma:SolidPeso molecular:835.11Setidegrasib
CAS:KRAS G12D inhibitor 17, a quinazoline-linked prolinamide, degrades mutant KRAS protein; a PROTAC.Fórmula:C60H65FN12O7SCor e Forma:SolidPeso molecular:1117.3LC 2 Epimer
CAS:<p>Negative control for LC 2.</p>Fórmula:C59H71ClFN11O7SCor e Forma:SolidPeso molecular:1132.8Tagarafdeg
CAS:Tagarafdeg (CFT1946) is a PROTAC degradator targeting mutant BRAF, capable of degrading BRAF V600E, G469A, G466V mutations, anti proliferation.Fórmula:C45H49F2N11O9SPureza:>99.99% - ＞99.99%Cor e Forma:SolidPeso molecular:958PROTAC K-Ras Degrader-1
CAS:PROTAC K-Ras Degrader-1 is a PROTAC degrader based on the Cereblon E3 ligase ligand, capable of degrading K-Ras.Fórmula:C53H62N10O10Pureza:98.05%Cor e Forma:SolidPeso molecular:999.12SS47
CAS:SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.Fórmula:C49H56N6O12SCor e Forma:SolidPeso molecular:953.07KRAS G12C inhibitor 69
KRAS G12C inhibitor 69 (Compound K09) is an inhibitor of the mutant RAS protein KRAS G12C with an IC50 of 4.36 nM. In the cell lines NCI-H358 and MIA-PACA-2, it suppresses ERK phosphorylation with IC50 values of 12 nM and 7 nM, respectively. Additionally, KRAS G12C inhibitor 69 hinders the proliferation of NCI-H358 and MIA-PACA-2 cancer cells, with IC50 values of 3.15 nM and 2.33 nM, respectively.Fórmula:C29H29ClF3N5O3Cor e Forma:SolidPeso molecular:588.02R18
CAS:14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Fórmula:C101H157N27O29S3Pureza:98%Cor e Forma:SolidPeso molecular:2309.69Rac1 Inhibitor W56
CAS:Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.Fórmula:C74H117N19O23SPureza:98%Cor e Forma:SolidPeso molecular:1671.93KRAS inhibitor-33
KRAS inhibitor-33 (compound 115a) is a pyrido[2,3-d]pyrimidine derivative that serves as an effective inhibitor of KRAS, exhibiting an IC50 value of ≤ 100nM.Fórmula:C33H39ClF2N6O3Cor e Forma:SolidPeso molecular:641.15
